185525-42-2

Basic information

• Product Name: TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE;tert-Butyl 3-hydroxyspiro[indan-1,4'-piperidine]-1'-carboxylate
• CAS NO: 185525-42-2
• Molecular Formula: C18H25NO3
• Molecular Weight: 303.4
• Mol File: 185525-42-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE(185525-42-2)
• EPA Substance Registry System: TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE(185525-42-2)

Safety Data

• Hazardous Substances Data: 185525-42-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE is used as a key intermediate for the synthesis of spiroindane growth hormone secretagogues. These secretagogues are designed to stimulate the release of growth hormone, which can have various therapeutic applications, such as promoting growth in children with growth hormone deficiencies or enhancing muscle growth and recovery in certain conditions.
The compound's role in the pharmaceutical industry is crucial, as it enables the development of drugs that can potentially improve the quality of life for individuals with growth-related health issues. By acting as a building block for the synthesis of growth hormone secretagogues, TERT-BUTYL 3-OXOSPIRO[INDAN-1,4'-PIPERIDINE]-1'-CARBOXYLATE contributes to the advancement of medical treatments and therapies in this field.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 95-13-6 1-indene 
• 13292-87-0 dimethylsulfide borane complex 
• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 

Downstream Products

• 159634-59-0 2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 

Relevant articles and documents

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

ANTAGONISTS OF PGD2 RECEPTORS

Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.

SPIRO-PIPERIDINE DERIVATIVES

Present invention is concerned with novel indol- 2-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention andlor treatment of anxiety and depressive disorders and other diseases. The compounds of present invention have the general Formula (I) wherein R1 to R 11 and X are as defined in the description

Spiropiperidine derivatives

A compound of the formula (I) wherein R1and R2is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group. A is CH2, CO or SO2. B is a single bond, alkylene or alkenylene. D is O or S. E is alkylene or alkenylene. wherein G is a substituted or unsubstituted cycloalkene ring, or a substituted cycloalkane ring. Ar is a substituted or unsubstituted aryl ring, or a substituted or unsubstituted heteroaryl ring. R3is alkyl. n is 1-3. The invention includes a pharmacologically acceptable salt, ester or other derivative of a compound of the formula (I). The invention also provides pharmaceutical compositions and methods of treating specified diseases utilizing a compound of formula (I).

The synthesis and activity of spiroindane growth hormone secretagogues

The synthesis and activities of a series of spiroindane growth hormone secretagogues is reported. Modification of the benzylic position of the spiroindane has resulted in a dramatic increase in potency resulting in subnanomolar peptidomimetic growth hormone secretagogues. In vivo data demonstrating the good oral activity of these analogs is reported.